RESI Innovation Challenge

LSN invites all global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health to apply for the RESI Innovation Challenge. Selected companies will showcase their technology in the exhibit hall and gain more visibility from the early-stage investors in attendance. Open to all companies attending RESI NYC 2018 November Conference: across Biotech, Medtech, Diagnostics & Digital Health.

If you are a scientist-entrepreneur or fundraising CEO starting to accumulate compelling proof-of-concept animal data or early stage clinical data, the RESI Innovation Challenge is for you. The 30 most innovative applicants will be hand selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge, presenting their technologies in an exhibition-style format throughout the full-day conference. Presenters will gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5- to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors, more frequently throughout the event.

Apply for RESI NYC Innovation Challenge

Application Deadline Is October 3rd, 2018

To add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 23,000 newsletter readership. Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!

NY & NJ Investor Pitch Challenge

All eligible tech hub constituents from New York and New Jersey are also invited to apply to the NY&NJ Investor Pitch Challenge and have the chance to pitch your technologies to a panel of investors.

  • Open to the constituents of NY & NJ incubators, tech transfer offices, universities, hospitals, and research labs .
  • Top 5 ranked companies of the NY & NJ tech hubs will present their technology as a 10-minute pitch to a panel of early-stage investors.
  • Boost your exposure to 400 investors
  • All finalists will be featured in the program guide, on the RESI website and announced in LSN’s newsletter to a readership of 23,000+
  • It is FREE to apply
Apply Now

RESI Boston 2018 Innovation Challenge Winners

First Prize:

The HeartLander System’s new approach to debilitating ventricular (heart) conditions comprises low cost disposables and an inexpensive, reusable controller: 1. Disposable sensor array placed on the outside of the torso 2. Disposable, tethered, percutaneously delivered, epicardial walker with multimodal sensing (e.g., Doppler ultrasound for avoiding coronaries) and insertable needle for saline-enhanced radiofrequency ablation (creates small, precise lesions) or for delivering therapy into the myocardium3. Control System that integrates sensor data, maps the heart defect, actuates the walker, plans actions, and provides a visualization display screen and control interface for the physician. Our first clinical focus (NIH-funded through animal PoC) is ventricular tachycardia, but the technology platform can be used for myocardial regeneration therapies, ventricular reshaping, and biventricular pacing.

Second Prize:

At BrainStem Biometrics we’re pioneering a new multi-billion medical device category to measure the most important part of the brain that no other company measures. Our first target is ICU medication safety- a much better way to administer essential but powerful sedative drugs to our most vulnerable ICU patients; the old and the young. Today most patients are over-medicated roughly 60% of the time because we have no effective way to measure the level of sedation. Administering sedatives in an optimal manner is proven to reduce length of stay and direct costs by 25% and to reduce 180-day risk of mortality significantly by 10% for tens of millions of intensive care patients. The company has initial sales, 510(k), long-life patents and is raising $800K to complete outcome studies and develop reference accounts.

Third Prize:

PhysioCue is on a mission to provide superior quality of life through revolutionary and scientifically proven technology to address epidemics of hypertension and migraine headache with noninvasive devices without side effects. Multinational proprietary technologies that specialized in thermoelectric and bio-sensors are empirically supported by renowned medical experts.

RESI Boston 2018 Innovation Challenge Companies

Therapeutic

Diagnostic

MedTech Device

Digital Health